Group 1: Earnings Performance - Aurora Cannabis Inc. reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share, representing a -36.36% earnings surprise [1] - The company posted revenues of $63.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.65%, compared to year-ago revenues of $49.98 million [2] - Over the last four quarters, Aurora Cannabis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Aurora Cannabis shares have increased by approximately 38.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.7% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.17 on revenues of $69.13 million, and $0.44 on revenues of $268.33 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Aurora Cannabis's stock performance [5] - The Zacks Rank for Aurora Cannabis is currently 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Exhibit 99.1 Aurora Cannabis Files Full Year Results and Announces Fiscal 2025 Fourth Quarter NASDAQ | TSX: ACB EDMONTON, AB, June 18, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2025 periods ending March 31, 2025. "We are pleased to report an exceptional year to our shareholders, highlighted by record annual global m ...

Here Are Ways Investing In Marijuana Stocks Can Make You MoneyMarijuana stocks hold lots of potential for home-run investments in the future. In 2018, most pot stocks saw their first wave of the green rush. Yet over the last several years, this has not been the case and things have changed drastically. Still, the way companies are keeping up with. Market demand profits and revenue are steadily rising. However, this success has played very little in how most marijuana stocks trade.But continued success durin ...

Industry Overview - The cannabis industry is experiencing consistent declines in stock prices despite long-term growth potential [1][2] - Investor confidence is low due to political uncertainty, particularly with Donald Trump's administration [2][3] Company Highlights - **Tilray Brands, Inc.**: Engages in the research, cultivation, processing, and distribution of medical cannabis products across multiple regions including Canada, the U.S., and Europe [4] - Recently ranked 4th in the Brewers Association 2024 annual report for top craft brewing companies in the U.S., up from 5th place, indicating growth in the craft brewing sector [6] - **Cronos Group Inc.**: Operates in the cultivation, production, distribution, and marketing of cannabis products internationally [7] - Anna Shlimak has been appointed as Chief Financial Officer, marking a significant leadership change within the company [9][10] - **Aurora Cannabis Inc.**: Involved in the production, distribution, and sale of cannabis products globally [10][12] - Recently launched the first inhalable resin cartridges for patients in the UK, Canada, and Australia, addressing a need for convenient consumption options [13]

Core Insights - Aurora Cannabis Inc. has been recognized in the Globe & Mail's 2025 Report on Business as an honouree in the Women Lead Here list, highlighting its commitment to gender diversity at the executive level [1][3] - The company boasts that 43% of its executive leadership team consists of women, emphasizing their role in driving change within the medical cannabis industry [2][3] - Aurora established the Women Empowerment Network (WEN) in 2022 to support the advancement of women within the organization, offering learning and community engagement opportunities [2] Company Overview - Aurora Cannabis Inc. is a leading global medical cannabis company based in Edmonton, Alberta, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [4] - The company's product portfolio includes various adult-use brands such as Drift, San Rafael '71, and medical cannabis brands like MedReleaf and CanniMed, among others [4] - Aurora is also a major player in the agricultural sector with a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants [4] Market Presence - Aurora's common shares are traded on NASDAQ and TSX under the symbol "ACB," indicating its established presence in the financial markets [5]

Core Insights - Aurora Cannabis Inc. is participating as a leader in the inaugural Global Cannabis Regulatory Summit (GCRS) in Washington, D.C. on March 26-27, 2025, highlighting its role in advocating for policy reform in the cannabis industry [1][2] Company Overview - Aurora Cannabis is a leading global medical cannabis company based in Canada, serving both medical and consumer markets across Canada, Europe, Australia, and New Zealand [3] - The company offers a diverse portfolio of adult-use brands including Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard, as well as medical cannabis brands such as MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co. [3] - Aurora also holds a controlling interest in Bevo Farms Ltd., a major supplier of propagated agricultural plants in North America [3] Industry Engagement - The GCRS will facilitate discussions among regulators, members of Congress, international policy experts, and cannabis industry executives to shape the future of the global cannabis industry [2][3] - Aurora's participation in panel discussions aims to enhance understanding of the distinctions between medical and adult-use cannabis, informed by international political and regulatory consensus [3]

Core Insights - Aurora Cannabis Inc. has discovered a novel source of genetic resistance against powdery mildew (PM2), which will enhance the protection of cannabis sativa against this pathogen [1][3] - The proprietary genetic marker technology developed will be integrated into Aurora's breeding program, aiming for commercial launch of powdery mildew resistant cultivars within the year [1][2] Industry Impact - This discovery addresses a significant challenge in the global cannabis industry, providing a sustainable solution for disease management and enhancing agricultural productivity [2][3] - The advancement in genetic research positions Aurora as a leader in the cannabis sector, differentiating it from competitors by focusing on scientific excellence and innovation [2][4] Research Collaboration - The research was led by Principal Scientist Jose Celedon in collaboration with The University of British Columbia, emphasizing the importance of breeding genetic resistance for sustainable agriculture [3][11] - The findings are documented in a peer-reviewed article, highlighting the scientific rigor behind the discovery [5][11] Business Strategy - Aurora's commitment to scientific research and innovation has resulted in improved potency and yield, ultimately reducing production costs and increasing efficiency [4] - The company aims to enhance biosecurity, reduce costs, and improve product quality through this genetic advancement, creating new market opportunities [3][9]

Industry Overview - Marijuana stocks are experiencing a downward trend due to regulatory uncertainty and oversupply in certain regions, leading to falling prices and negatively impacting revenue [1][2] - Despite the challenges, the cannabis industry as a whole continues to grow, with many companies reporting stronger profits and gains in recent earnings reports [2] Investment Opportunities - Current market conditions may present a buying opportunity for investors, as the sector is at a low point [2] - Shareholders are advised to conduct thorough research and monitor the sector closely, as the cannabis industry is still developing and may see positive changes [3] Company Highlights - **Aurora Cannabis Inc.**: Engages in the production, distribution, and sale of cannabis products, recently announced an expansion of pastille offerings in Australia [4][6] - **SNDL Inc.**: Operates in the cannabis sector with various segments, recently reported Q4 2024 and full-year earnings [7][9] - **Cronos Group Inc.**: Focuses on cultivation and marketing of cannabis products, recently appointed Anna Shlimak as CFO [12][13] Financial Performance - **Cronos Group Inc.**: Reported net revenue of $257.7 million for Q4 2024 and $920.4 million for the full year, with gross profit reaching $68.8 million in Q4 and $240.3 million for the year [14]

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]

Industry Overview - The cannabis industry is expanding beyond traditional flower sales to include edibles, oils, and wellness products, attracting a broader consumer base [1] - Partnerships among companies to create and release new products are positively impacting the industry [1] Market Dynamics - Companies demonstrating productivity and profitability can influence the trading of marijuana stocks, amidst speculation and volatility [2] - Legal operators are showing progress, leading to improved financial results driven by higher sales, operational efficiencies, and better supply chain management [2] - Evolving regulations are becoming more transparent and standardized, reducing uncertainty for investors and companies [2] Investment Insights - Monitoring trends within the public cannabis sector can provide insights into which marijuana stocks may perform better [3] - A strategic approach is essential for investors to capitalize on market movements, as pot stocks often exhibit unpredictable trading patterns [3] Company Highlights - **Cronos Group Inc.**: Engages in the cultivation, production, and marketing of cannabis products in Canada, Israel, and Germany [4][6] - **Aurora Cannabis Inc.**: Reported Q4 2024 net revenue of $30.3 million, an increase of $6.4 million from Q4 2023, with gross profit rising to $10.8 million [9] - **Canopy Growth Corporation**: Announced a new at-the-market equity program allowing the issuance and sale of up to US$200 million of common shares [13]